Lenvatinib vs Sorafenib — Which Comes First for Liver Cancer?

Head-to-head trials show lenvatinib produces higher response rates and longer time without disease progression. However, overall survival was similar between the two in the REFLECT trial, which is the outcome that matters most. Neither drug is simply better in an absolute sense — the right choice depends on your tumour extent, portal vein involvement, liver function, other health conditions and cost. Both NCCN and ESMO list both as standard options, which is why both remain in routine use.

Switching between these two drugs when one stops working is not standard practice, because they target similar pathways and tumour resistance to one often extends to the other. If sorafenib is no longer controlling the cancer, your oncologist will assess second-line options from different drug classes. Ask your team what their plan is if the current drug becomes less effective — having that conversation before it happens is useful.

Lenvatinib is prescribed at one of two doses depending on body weight, because studies showed that body weight affects how much of the drug reaches the bloodstream. The adjustment is designed to keep the drug at a level that is effective without increasing side effects unnecessarily. Sorafenib does not have a weight-based adjustment. If your weight changes significantly during treatment, mention it to your team — they may reassess your dose.

Hand-foot syndrome — redness, soreness, blistering and peeling on the palms and soles — is a known side effect of both drugs, but it is more common and often more severe with sorafenib. It can make walking and daily tasks painful if it is not managed early. Starting a moisturising routine before your first dose, wearing comfortable shoes, and reporting the first sign of redness to your team are the most useful steps. It rarely settles on its own without a dose adjustment or a short break from treatment.

Portal vein involvement is a reason your oncologist may choose sorafenib over lenvatinib. The REFLECT trial excluded patients with main portal vein invasion, so there is limited safety data for lenvatinib in that situation. Sorafenib does not carry the same exclusion and has been used in patients with portal vein thrombosis. Your oncologist will weigh this alongside your liver function, bilirubin level and the overall extent of disease before deciding.

Generic versions of sorafenib are approved by CDSCO on the basis that they contain the same active ingredient at the same dose and reach the bloodstream in a comparable way — this is what bioequivalence means. In routine clinical practice, most patients managed on a generic version do as well as those on the branded version. If you notice any change after switching brands — a different tablet appearance, a new side effect or a change in how you feel — tell your pharmacist or oncologist rather than stopping the drug.